Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)

著者: C. Zhou, Yi‐Long Wu, G. Chen, J. Feng, Xuetong Liu, C. Wang, S. Zhang, J. Wang, Songwen Zhou, Shengxiang Ren, Shun Lü, L. Zhang, Chengping Hu, Chengping Hu, Yi Luo, Lin Chen, M. Ye, Juanjuan Huang, X. Zhi, Y. Zhang, Qingyu Xiu, W. F. Mader, L. Zhang, Changxuan You - Annals of Oncology 2015 被引用: 468